Total Funding
29
52
Total FundingVenture - Series Unknown raised
Growth Score
-2 pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
162882
Azadyne is a new approach to the treatment of autoimmune diseases.
- Jason Rutt: CEO
About the Company
Azadyne’s novel approach to treating autoimmune disease focuses on an unexplored pathway in the body and is based on research conducted at Trinity by Associate Professor in Biochemistry Vincent Kelly, Professor of Synthetic Chemistry Professor Stephen Connon and assistant Professor in Chemistry John Michael Southern.
